GB811757A - Production of an antibiotic designated antibiotic 101a fermentation - Google Patents
Production of an antibiotic designated antibiotic 101a fermentationInfo
- Publication number
- GB811757A GB811757A GB32304/56A GB3230456A GB811757A GB 811757 A GB811757 A GB 811757A GB 32304/56 A GB32304/56 A GB 32304/56A GB 3230456 A GB3230456 A GB 3230456A GB 811757 A GB811757 A GB 811757A
- Authority
- GB
- United Kingdom
- Prior art keywords
- antibiotic
- components
- suspensions
- acid
- produced
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
- C12N1/205—Bacterial isolates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P1/00—Preparation of compounds or compositions, not provided for in groups C12P3/00 - C12P39/00, by using microorganisms or enzymes
- C12P1/04—Preparation of compounds or compositions, not provided for in groups C12P3/00 - C12P39/00, by using microorganisms or enzymes by using bacteria
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
- C12R2001/465—Streptomyces
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Biomedical Technology (AREA)
- Virology (AREA)
- Medicinal Chemistry (AREA)
- Mycology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
An antibiotic designated antibiotic 101a is produced by cultivating Streptomyces spectabilis NRRL 2494 novspec, or a variant or mutant thereof, in an aqueous nutrient medium containing assimilable carbohydrate and proteinaceous material under aerobic and preferably submerged aerobic conditions. An initial pH of 6.5 to 7.5, a temperature of cultivation of 24 DEG to 37 DEG C. and preferably 28 DEG to 34 DEG C. and a duration of cultivation of 2 to 6 days is employed. Specified sources of (a) carbohydrate are glucose, dextrin, molasses, starch, maltose, galactose, mannitol and soybean oil; (b) nitrogen are soybean meal, fish meal, cotton seed meal, defatted soybean meal, peanut meal, brewers' yeast, corn gluten and corn steep <PICT:0811757/IV (b)/1> <PICT:0811757/IV (b)/2> extraction or (b) adsorption on carbon followed by elution. The broth is filtered at pH 4 to 8, extracted with a water-immiscible organic solvent, the extract concentrated to a solid which is redissolved in a solvent and 101a is precipitated by the addition of a non-solvent, e.g. n-hexane. Typical solvents are alkyl acetates, e.g. ethyl acetate and amyl acetate, aliphatic ketones such as methyl ethyl ketone, halogenated aliphatic hydrocarbons such as methylene chloride and hydrocarbons such as benzene. The antibiotic 101a isolated from most beers contains five antibiotically active components designated 101a-1, 101a-2, 101a-3, 101a-4 and 101a-5. Additional components 101a-6 and 101a-7 have been observed in some beers. In benzene-methanol-water, the Rf values of these components are 0.65, 0.35, 0.75, 0.85 (4 and 5 together), 0.25 and 0.55 respectively. The components are partially separated by (a) partition chromatography and (b) Craig countercurrent extraction, a combination of (a) and (b) being necessary to obtain complete separation. A water-ethanol-cyclohexane-ethyl acetate (1 : 1 : 1 : 1) solvent system may be used in the Craig extraction process. Component 101a-2 is converted to the other components by treatment liquor. Other additions are (a) inorganic salts, e.g. such as produce ions of potassium, sodium, calcium, phosphate and sulphur; (b) trace elements. Antibiotic 101a is recovered by (a) with (a) acetic anhydride, (b) p-toluene sulphonate and glacial acetic acid, and (c) ammonia and ethanol. In the case of (b), component 101a-1 only is produced. Crystalline 101a samples melt at 155 DEG to 255 DEG C.; show ultraviolet absorption maxima at 435 mm and 245 mm ; contain 63.64 per cent carbon, 6.89 per cent hydrogen and 1.68 per cent nitrogen, the balance being oxygen; soluble in alcohols such as methanol, alkyl acetates such as amyl acetate, alkyl ketones such as methyl ethyl ketone, chlorinated aliphatic hydrocarbons such as methylene chloride, dioxane; substantially insoluble in n-hexane, water and ethers; unstable in alkali, stable at pH 2 to 6; infra-red absorption spectrum as in Fig. 2; neutral or weakly acidic hydrolysing on treatment with dilute alkali; forms helianthate with alcoholic solution of methyl orange; forms acyl derivatives with acylating agents, e.g. acetyl and benzoyl derivatives; active against a wide range of micro-organisms including pneumococci, staphylococci and M. tuberculosis. Antibiotic 101a and its components are used in formulations for the treatment of man and animals (see Group VI). The characteristics of components 101a-1 to 101a-7 are as follows: <TABS:0811757/IV (b)/1> Vitamin B12 is produced by growing Streptomyces spectabilis NRRL 2494 in a nutrient medium containing cobalt ions. A steroid oxidized in the 11 position is obtained using S. spectabilis in the presence of a steroid precursor such as progesterone or Reichstein's compound S. or S. acetate.ALSO:Antibiotic 101a, or a component thereof (i.e. antibiotics 101a-1, 101a-2, 101a-3, 101a-4, 101a-5, 101a-6, 101a-7), produced by Streptomyces spectabilis NRRL 2494 nov/spec. (see Group IV(b)), alone or in admixture with other antibiotics or therapeutic agents is employed as a feed supplement in promoting the growth of animals and poultry.ALSO:Antibiotic 101a, or a component thereof (i.e. antibiotics 101a-1, 101a-2, 101a-3, 101a-4, 101a-5, 101a-6 or 101a-7), produced by culturing Streptomyces spectabilis NRRL 2494 Nov. spec. (see Group IV (b)), as such or in admixture with a pharmaceutical carrier is used in the treatment of microbial infections especially staphylococcal, streptococcal and tubercular diseases of man and animals. Suitable formulations are tablets, capsules, powders, granules, aqueous solutions or suspensions and suspensions in edible oils for oral or parenteral use. The suspensions may contain a suspending agent such as gelatin, tragacanth, methyl cellulose, sodium carboxymethyl cellulose and polyvinyl pyrrolidone. Suspensions in an edible oil such as coconut or peanut oil may contain aluminium, monostearate. Topical preparations include ointments made with petroleum-type grease bases or water-soluble polyethylene glycol bases; creams, emulsions, lotions, sprays and suppositories. For veterinary use, the preparations are used in the form of bougies, capsules, tablets, ointments and oil suspensions. Antibiotic 101a may be used in admixture with (a) antitubercular drugs such as isonicotinic acid hydrazide, streptomycin and/or dihydrostreptomycin, p-aminosalicylic acid and salts thereof, cycloserine; a combination of isonicotinic acid hydrazide and p-aminosalicylic acid and salts thereof; and a combination of streptomycin, isonicotinic acid hydrazide and p-aminosalicylic acid and the salts thereof, (b) sulpha drugs such as sulphadiazine, sulphamerazine and sulphamethazine, (c) other antibiotics such as tetracycline, oxytetracycline, chlortetracycline, neomycin, polymyxin, chloramphenicol, penicillins G, O and V, novobiocin, bacitracin, streptothricin, circulin and erythromycin, (d) vitamins such as thiamin, riboflavin, ascorbic acid, niocinamide, pyridoxine, pantothenic acid, Vitamin B12 and folic acid, (e) corticoids such as cortisone, hydracortisone, and esters thereof; D 1-cortisone and D 1-hydrocortisone and their 21-position esters, e.g. acetate, cyclopentylpropionate and succinate; alkyl substituted cortisones and hydrocortisones such as 2-methylhydrocortisone and 6-methylhydrocortisone and esters thereof, (f) other drugs. Antibiotic 101a may be mixed with animal (including poultry) feed compositions for the treatment of disease.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US811757XA | 1955-11-09 | 1955-11-09 |
Publications (1)
Publication Number | Publication Date |
---|---|
GB811757A true GB811757A (en) | 1959-04-08 |
Family
ID=22162558
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
GB32304/56A Expired GB811757A (en) | 1955-11-09 | 1956-10-23 | Production of an antibiotic designated antibiotic 101a fermentation |
Country Status (1)
Country | Link |
---|---|
GB (1) | GB811757A (en) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE1181860B (en) * | 1959-10-20 | 1964-11-19 | Upjohn Co | Method of Isolating Actinospectacin |
US3240787A (en) * | 1962-01-23 | 1966-03-15 | Inst Medical Res | Alpha-hydroxymethyl-n-[omega-hydroxamic-acid-ethylene-carbonylamino-methylene-carbonyl]-pyrrolidine and process for its production |
US3859170A (en) * | 1960-05-20 | 1975-01-07 | Abbott Lab | Method of producing antimicrobial agent m-141 and its salts |
WO2001070213A2 (en) * | 2000-03-23 | 2001-09-27 | Influx, Inc. | Bactericidal antimicrobial methods and compositions for use in treating gram positive infections comprising an antibiotic potentiator having acyl hydrazide oxy amide or 8-hydroxy quinoline structure |
-
1956
- 1956-10-23 GB GB32304/56A patent/GB811757A/en not_active Expired
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE1181860B (en) * | 1959-10-20 | 1964-11-19 | Upjohn Co | Method of Isolating Actinospectacin |
US3234092A (en) * | 1959-10-20 | 1966-02-08 | Upjohn Co | Actinospectacin and process for producing same |
US3859170A (en) * | 1960-05-20 | 1975-01-07 | Abbott Lab | Method of producing antimicrobial agent m-141 and its salts |
US3240787A (en) * | 1962-01-23 | 1966-03-15 | Inst Medical Res | Alpha-hydroxymethyl-n-[omega-hydroxamic-acid-ethylene-carbonylamino-methylene-carbonyl]-pyrrolidine and process for its production |
WO2001070213A2 (en) * | 2000-03-23 | 2001-09-27 | Influx, Inc. | Bactericidal antimicrobial methods and compositions for use in treating gram positive infections comprising an antibiotic potentiator having acyl hydrazide oxy amide or 8-hydroxy quinoline structure |
WO2001070213A3 (en) * | 2000-03-23 | 2003-01-09 | Influx Inc | Bactericidal antimicrobial methods and compositions for use in treating gram positive infections comprising an antibiotic potentiator having acyl hydrazide oxy amide or 8-hydroxy quinoline structure |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US3338786A (en) | Antibiotic av290 and production thereof | |
Berger et al. | A new antibiotic X-5108 of Streptomyces origin I. Production, isolation and properties | |
US2931798A (en) | Kanamycin and processes for the preparation thereof | |
US3116202A (en) | Antibiotic streptovaricin and process for its production | |
US4024251A (en) | Antibiotic FR-02A and therapeutic compositions thereof | |
Pettinga et al. | The isolation of a second crystalline antibiotic from Streptomyces erythreus | |
GB811757A (en) | Production of an antibiotic designated antibiotic 101a fermentation | |
US3094460A (en) | Decoyinine | |
Arai et al. | Copiamycin, a new antifungal antibiotic derived from S. hygroscopicus var. chrystallogenes | |
US2990325A (en) | Antibiotics | |
US3160560A (en) | Streptolydigin and production thereof | |
US3674866A (en) | Moenomycin and process for producing same | |
US3022311A (en) | Yohimbine and alpha-yohimbine derivatives | |
US3423398A (en) | Sangivamycin and derivatives thereof | |
US3819611A (en) | Antibiotic w847 (megalomicin)and methods for production thereof | |
US2902412A (en) | Fermentative carbomycin production | |
GB925481A (en) | A new antibiotic streptozotocin | |
US3207750A (en) | Derivatives of decoyinine | |
US4065356A (en) | Production of antibiotic FR-02A (efrotomycin) by streptomyces lactamdurans | |
US3089816A (en) | Lemacidine and process for its manufacture | |
GB901273A (en) | The new organic compound tylosin, its hydrolysis product desmycosin and methods for preparing same | |
US3377243A (en) | Antibiotic ra-6950beta and method of production using streptomyces ochrosporus | |
US3142671A (en) | Glebomycin and salts thereof | |
US3296295A (en) | Norsteroids | |
US4296101A (en) | Antibiotic kristenin |